Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 May 2014Website:
http://www.aldeyra.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:56:54 GMTDividend
Analysts recommendations
Institutional Ownership
ALDX Latest News
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled to begin at 8:00 a.m. ET today. Pipeline Updates Following positive biomarker results in adults, including near-normalization o.
Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye disease and allergic conjunctivitis. Aldeyra plans to resubmit Reproxalap's new drug application by Q4 2024, with potential FDA approval by Q2 2025, which could trigger potential milestone payments and revenue opportunities.
Here is the performance comparison of Aldeyra Therapeutics, Inc. (ALDX) and Teva Pharmaceutical Industries Ltd. (TEVA) with their sector year-to-date.
Aldeyra Therapeutics (NASDAQ: ALDX) recently announced its first quarter 2024 results, with earnings per share of -14 cents.
Although the number and size of insider purchases have been somewhat lower as the second quarter begins, the following beneficial owners and other insiders were still showing their love for these five stocks.
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BOX's fiscal third-quarter results are likely to reflect strength in content cloud solutions.
- 1(current)
What type of business is Aldeyra Therapeutics?
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
What sector is Aldeyra Therapeutics in?
Aldeyra Therapeutics is in the Healthcare sector
What industry is Aldeyra Therapeutics in?
Aldeyra Therapeutics is in the Biotechnology industry
What country is Aldeyra Therapeutics from?
Aldeyra Therapeutics is headquartered in United States
When did Aldeyra Therapeutics go public?
Aldeyra Therapeutics initial public offering (IPO) was on 02 May 2014
What is Aldeyra Therapeutics website?
https://www.aldeyra.com
Is Aldeyra Therapeutics in the S&P 500?
No, Aldeyra Therapeutics is not included in the S&P 500 index
Is Aldeyra Therapeutics in the NASDAQ 100?
No, Aldeyra Therapeutics is not included in the NASDAQ 100 index
Is Aldeyra Therapeutics in the Dow Jones?
No, Aldeyra Therapeutics is not included in the Dow Jones index
When does Aldeyra Therapeutics report earnings?
The next expected earnings date for Aldeyra Therapeutics is 02 August 2024